Shots:

• The approval is based on P-III KEYNOTE-426 study assessing Keytruda + Inlyta (axitinib) vs Sunitinib as a 1L treatment for patients advanced RCC
• The P-III KEYNOTE-426 study results: improvement in OS & PFS; 31% reduction in the risk of progression of disease or death; ORR (59% vs 36%); 5yrs. the survival rate for advanced RCC is estimated to be 8%
• Merck & Co’s (MSD outside the United States and Canada) Keytruda is an anti-PD-1 therapy- act by blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 thus activating T lymphocytes affecting both tumor and healthy cells

Click here to­ read full press release/ article 

Ref: Newswire Canada | Image: Merck & Co